ACT-128800 in Psoriasis

Actelion Pharmaceuticals logo

Actelion Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Plaque Psoriasis

Treatments

Drug: Placebo
Drug: ACT-128800

Study type

Interventional

Funder types

Industry

Identifiers

NCT00852670
AC-058A200

Details and patient eligibility

About

This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

Enrollment

66 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified.

Exclusion criteria

  • Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.
  • Systemic or topical treatments for psoriasis other than emollients.
  • Ongoing bacterial, viral or fungal infections.
  • History or presence of malignancy.
  • Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

66 participants in 2 patient groups, including a placebo group

A
Experimental group
Treatment:
Drug: ACT-128800
B
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems